Literature DB >> 23884895

Incidental medullary thyroid microcarcinoma revealed by mild increase of preoperative serum calcitonin levels: therapeutic implications.

Isabella Merante Boschin1, Francesca Torresan, Antonio Toniato, Mariangela Zane, Eric Casal Ide, Gianmaria Pennelli, Lucia Rampin, Patrick M Colletti, Domenico Rubello, Maria Rosa Pelizzo.   

Abstract

To investigate whether further, diagnostic procedures should be recommended in patients with slight increase of preoperative serum basal calcitonin (bCT) levels in whom surgical treatment can be recommendable. Fourteen consecutive patients with nodular thyroid disease underwent thyroidectomy in our center for suspected medullary thyroid microcarcinoma (MTC) because their serum bCT levels were slightly higher than the upper limit of normal range. Serum bCT was measured by radioimmunoassay, normality range = 0-20 ng/L. Surgical specimens were examined by the same pathologist using histologic and immunohistochemistry techniques. An extensive search for parafollicular C-cell hyperplasia (CCH) and/or microscopic MTC foci was performed. At preoperative ultrasound, a single thyroid nodule was depicted in three patients while a multinodular goiter in 11. The bCT values ranged between 24.4 and 94.6 ng/L, median 42.2 ng/L while the pentagastrin-stimulated CT (sCT) values by pentagastrin test ranged between 61.5 and 1,262 ng/L, median 245.0 ng/L. Total thyroidectomy was performed in 13 patients, and lobectomy in the other one; central node dissection was also performed in eight cases. At histology, MTC was diagnosed in nine patients (64.3 %), showing a median maximum diameter of 6.1 mm (range, 1.5-17 mm); CCH was diagnosed in the other five patients (35.7 %). The pentagastrin stimulation test was obtained in all patients. It is worth noting that a very high increase of sCT >100 ng/mL was observed in 5/9 patients with MTC and in 2/4 patients with HCC, therefore suggesting the absence of a relationship between the entity of response to pentagastrin test with a specific pathology (MTC vs. HCC). In six patients, the MTC was the nodule on which preoperative FNAC had been performed, while in other three patients preoperative FNAC had been performed on a different nodule from the MTC. Based on our experience, in case of the pentagastrin stimulation test with sCT <100 ng/L and a single nodule, the CT assay on FNAC may be useful, subsequently lobectomy with definitive histological diagnosis is recommended. In case of the Pg test with sCT <100 ng/L and bilateral goiter, total thyroidectomy with histological diagnosis is recommended. In this way, as for the surgical procedure, total thyroidectomy is recommended in cases of bilateral goiter, while lobectomy can be offered for cases with single nodes with serum dosage of bCT in the strict follow up. In case of the pentagastrin stimulating test with sCT <100 ng/L and bilateral goiter, total thyroidectomy with histological diagnosis is recommended.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23884895     DOI: 10.1007/s12020-013-0019-7

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  19 in total

1.  Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease.

Authors:  Zubair Baloch; Pierre Carayon; Bernard Conte-Devolx; Laurence M Demers; Ulla Feldt-Rasmussen; Jean-François Henry; Virginia A LiVosli; Patricia Niccoli-Sire; Rhys John; Jean Ruf; Peter P A Smyth; Carole A Spencer; Jan R Stockigt
Journal:  Thyroid       Date:  2003-01       Impact factor: 6.568

2.  Frequency and relevance of elevated calcitonin levels in patients with neoplastic and nonneoplastic thyroid disease and in healthy subjects.

Authors:  Georgios Karanikas; Abbas Moameni; Christian Poetzi; Georg Zettinig; Klaus Kaserer; Christian Bieglmayer; Bruno Niederle; Robert Dudczak; Christian Pirich
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

3.  Histopathological and molecular studies in patients with goiter and hypercalcitoninemia: reactive or neoplastic C-cell hyperplasia?

Authors:  Uberta Verga; Stefano Ferrero; Leonardo Vicentini; Tatiana Brambilla; Valentina Cirello; Marina Muzza; Paolo Beck-Peccoz; Laura Fugazzola
Journal:  Endocr Relat Cancer       Date:  2007-06       Impact factor: 5.678

4.  Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma.

Authors:  F Pacini; M Fontanelli; L Fugazzola; R Elisei; C Romei; G Di Coscio; P Miccoli; A Pinchera
Journal:  J Clin Endocrinol Metab       Date:  1994-04       Impact factor: 5.958

5.  Comparison of three methods of DNA extraction from peripheral blood mononuclear cells and lung fragments of equines.

Authors:  E M Santos; J F R Paula; P M C Motta; M B Heinemann; R C Leite; J P A Haddad; H L Del Puerto; J K P Reis
Journal:  Genet Mol Res       Date:  2010-08-17

6.  Comparison of calcium and pentagastrin tests for the diagnosis and follow-up of medullary thyroid cancer.

Authors:  Carla Colombo; Uberta Verga; Caterina Mian; Stefano Ferrero; Michela Perrino; Leonardo Vicentini; Davide Dazzi; Giuseppe Opocher; Maria Rosa Pelizzo; Paolo Beck-Peccoz; Laura Fugazzola
Journal:  J Clin Endocrinol Metab       Date:  2011-12-14       Impact factor: 5.958

7.  Sporadic hypercalcitoninemia: clinical and therapeutic consequences.

Authors:  C Scheuba; K Kaserer; A Moritz; R Drosten; H Vierhapper; C Bieglmayer; O A Haas; B Niederle
Journal:  Endocr Relat Cancer       Date:  2008-11-05       Impact factor: 5.678

8.  Potency and tolerance of calcitonin stimulation with high-dose calcium versus pentagastrin in normal adults.

Authors:  Patricia Doyle; Christian Düren; Kai Nerlich; Frederik A Verburg; Inge Grelle; Hanne Jahn; Martin Fassnacht; Uwe Mäder; Christoph Reiners; Markus Luster
Journal:  J Clin Endocrinol Metab       Date:  2009-06-02       Impact factor: 5.958

9.  Is basal ultrasensitive measurement of calcitonin capable of substituting for the pentagastrin-stimulation test?

Authors:  Géraldine Pina; Séverine Dubois; Arnaud Murat; Nicole Berger; Patricia Niccoli; Jean-Louis Peix; Régis Cohen; Claudine Guillausseau; Anne Charrie; Olivier Chabre; Catherine Cornu; Françoise Borson-Chazot; Vincent Rohmer
Journal:  Clin Endocrinol (Oxf)       Date:  2013-03       Impact factor: 3.478

10.  Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin: comparison with genetic screening in hereditary medullary thyroid carcinoma.

Authors:  N Barbot; C Calmettes; I Schuffenecker; J P Saint-André; B Franc; V Rohmer; P Jallet; J C Bigorgne
Journal:  J Clin Endocrinol Metab       Date:  1994-01       Impact factor: 5.958

View more
  5 in total

1.  Comparison of side effects of pentagastrin test and calcium stimulation test in patients with increased basal calcitonin concentration: the gender-specific differences.

Authors:  Philipp Ubl; Tatiana Gincu; Mohammad Keilani; Lothar Ponhold; Richard Crevenna; Bruno Niederle; Marcus Hacker; Shuren Li
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

2.  The essential use of FNA-calcitonin for detecting medullary thyroid cancer.

Authors:  P Trimboli; L Guidobaldi; A Crescenzi; M Bongiovanni; L Giovanella
Journal:  Endocrine       Date:  2014-03-08       Impact factor: 3.633

3.  Evaluation of neutrophil-to-lymphocyte ratio and calcitonin concentration for predicting lymph node metastasis and distant metastasis in patients with medullary thyroid cancer.

Authors:  Nizhen Xu; Yanbing Jian; Yaxi Wang; Wen Tian
Journal:  Mol Clin Oncol       Date:  2018-09-27

4.  Clinicopathological Significance and Prognosis of Medullary Thyroid Microcarcinoma: A Meta-analysis.

Authors:  Jin Hwa Kim; Jung-Soo Pyo; Won Jin Cho
Journal:  World J Surg       Date:  2017-10       Impact factor: 3.352

5.  Clinical value of color Doppler ultrasound combined with serum tumor markers for the diagnosis of medullary thyroid carcinoma.

Authors:  Xue Yang; Jinjuan Xu; Jilan Sun; Lizhi Yin; Rui Guo; Zhimei Yan
Journal:  Oncol Lett       Date:  2021-05-27       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.